Want to see FR:BIM full AI Analyst Report?
Top Page
bioMerieux
(BIM)
Select Model
Select Model
Rating:71Outperform
Price Target:
€93.00
▲(23.18% Upside)
Action:Upgraded
Date:08/06/26
The score is driven primarily by solid financial fundamentals—especially a conservative balance sheet and improving recent free cash flow—tempered by softer revenue/profit momentum versus earlier years. Technicals are mixed with neutral momentum but longer-term trend weakness, while valuation appears broadly fair with a modest dividend yield.
Positive Factors
Conservative balance sheet
Low leverage and a large equity base provide bioMérieux with financial resilience and flexibility. This reduces balance-sheet risk while preserving capacity to support research, platform investment, customer deployments, and other long-term priorities through changing business conditions.
Negative Factors
Recent revenue contraction
The 2025 revenue decline shows that recent top-line momentum has weakened after several years of expansion. Continued softness could limit operating leverage, reduce the resources available for investment, and make future growth increasingly dependent on menu expansion or higher testing volumes.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage and a large equity base provide bioMérieux with financial resilience and flexibility. This reduces balance-sheet risk while preserving capacity to support research, platform investment, customer deployments, and other long-term priorities through changing business conditions.
Read all positive factors
bioMerieux (BIM) vs. iShares MSCI France ETF (EWQ)
Market Cap
€9.95B
Dividend Yield1.15%
Average Volume (3M)164.81K
Price to Earnings (P/E)21.7
Beta (1Y)0.61
Revenue Growth-3.18%
EPS Growth22.52%
CountryFR
Employees14,894
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)3.93
Shares Outstanding118,361,220
10 Day Avg. Volume181,338
30 Day Avg. Volume164,809
Financial Highlights & Ratios
PEG Ratio-4.00
Price to Book (P/B)3.17
Price to Sales (P/S)3.20
P/FCF Ratio28.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€75.80Price Target Upside0.40% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)4.41
Revenue Forecast (FY)€4.14B
bioMerieux Business Overview & Revenue Model
Company Description
bioMérieux S.A. is a global entity operating across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, specializing in the development and production of in vitro diagnostic solutions. The company's sophisticated systems utilize b...
How the Company Makes Money
bioMérieux primarily generates revenue by selling in vitro diagnostic solutions that combine (1) installed instruments and (2) recurring consumables and services that run on those instruments. Key revenue streams typically include:
1) Reagents, t...
bioMerieux Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
84
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.99B | 4.07B | 3.98B | 3.67B | 3.59B | 3.38B |
| Gross Profit | 2.08B | 2.14B | 2.22B | 2.06B | 1.96B | 1.97B |
| EBITDA | 917.10M | 999.60M | 897.50M | 701.30M | 811.90M | 977.80M |
| Net Income | 462.40M | 397.50M | 432.20M | 357.60M | 452.40M | 601.10M |
Balance Sheet | ||||||
| Total Assets | 5.69B | 5.57B | 5.77B | 5.26B | 5.19B | 4.61B |
| Cash, Cash Equivalents and Short-Term Investments | 657.70M | 569.80M | 449.80M | 352.40M | 552.60M | 803.50M |
| Total Debt | 421.80M | 461.40M | 490.70M | 518.80M | 505.40M | 462.50M |
| Total Liabilities | 1.39B | 1.47B | 1.56B | 1.51B | 1.54B | 1.44B |
| Stockholders Equity | 4.30B | 4.10B | 4.20B | 3.75B | 3.60B | 3.11B |
Cash Flow | ||||||
| Free Cash Flow | 585.50M | 453.00M | 321.50M | 107.10M | 188.40M | 534.60M |
| Operating Cash Flow | 907.60M | 788.30M | 667.30M | 445.40M | 475.10M | 824.70M |
| Investing Cash Flow | -348.70M | -461.70M | -359.80M | -488.80M | -528.10M | -307.30M |
| Financing Cash Flow | -277.50M | -155.40M | -212.60M | -122.30M | -244.20M | -140.60M |
bioMerieux Technical Analysis
Positive
75.50
Price Trends
74.93
Positive
72.63
Positive
81.51
Positive
Market Momentum
2.33
Negative
75.04
Negative
90.41
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BIM, the sentiment is Positive. The current price of 75.5 is below the 20-day moving average (MA) of 77.06, above the 50-day MA of 74.93, and below the 200-day MA of 81.51, indicating a bullish trend. The MACD of 2.33 indicates Negative momentum. The RSI at 75.04 is Negative, neither overbought nor oversold. The STOCH value of 90.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:BIM.
bioMerieux Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | €9.95B | 21.73 | 11.01% | 1.15% | -3.18% | 22.52% | |
69 Neutral | €2.66B | 17.50 | 13.31% | 0.45% | 4.30% | 17.11% | |
62 Neutral | €20.71B | 70.73 | 7.11% | 0.32% | 3.76% | 29.94% | |
59 Neutral | €13.67B | 26.15 | 14.81% | 0.92% | 3.38% | 28.21% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
FR:BIM
bioMerieux
85.40
-21.63
-20.21%
FR:ERF
Eurofins Scientific
78.46
17.17
28.01%
FR:DIM
Sartorius Stedim Biotech
213.60
31.49
17.29%
FR:VIRP
Virbac SA
325.00
18.85
6.16%
FR:ALECR
Eurofins-Cerep SA
18,100.00
500.00
2.84%
FR:ALBIO
Biosynex SA
0.85
0.17
25.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.